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One of the main challenges in cancer chemotherapy is to
develop drugs that selectively target cancer cells in order to
reduce general toxicity and consequently side effects. One
such targeting method involves using large carrier com-
pounds that release a drug once inside a cancer cell, since
large compounds selectively accumulate in cancer tissue due
to the “enhanced permeability and retention effect”.[1] Re-
cently, we have shown that the encapsulation of a hydropho-
bic metallo-drug guest in a water-soluble hexacationic arene
ruthenium cage delivery vector produces a synergistic effect,
due to the modest cytotoxicity of the cage itself, and the cy-
totoxicity of the encapsulated guest compound.[2] We have
now encapsulated in the cavity of [Ru6(p-iPrC6H4Me)6 ACHTUNGTRENNUNG(tpt)2-
ACHTUNGTRENNUNG(C6H2O4)3]
6+ (1) (tpt=2,4,6-tris(pyridin-4-yl)-1,3,5-triazine),
an intrinsically fluorescent pyrenyl compound (pyrene-R=
1-(4,6-dichloro-1,3,5-triazin-2-yl)pyrene), thus giving rise to
the hexanuclear metalla-prism [pyrene-R1]6+ , in which the
pyrenyl derivative occupies the cavity of 1. The fluorescence
of pyrene-R is quenched inside the metalla-prism cavity. A
study of this new system has provided direct evidence that
once inside the cell, the hexaruthenium cage releases the
fluorescent guest, thus confirming our initial hypothesis that
cage 1 can act as a Trojan horse for cancer cells.[2] In addi-
tion, experiments into the uptake mechanism indicate that
an assisted diffusion pathway is in operation.
The encapsulation of guest molecules in coordinationally
driven self-assembled cage compounds has been extensively
studied.[3] The encapsulation process depends on the com-
plementary of the guests size, shape, and chemical surface
with respect to that of the host cavity. Potential applications
of these systems have been found in chemistry (recognition
and selective transformations), biology (translocation of
drugs across membranes, sensors, biomimetics), and material
science (construction of macroscopic architectures for stor-
age and devices at the molecular level).[3]
Additionally, ruthenium complexes have considerable po-
tential in a number of biomedical applications such as diag-
nostics and therapeutics and a wide range of ruthenium
compounds have been evaluated as putative anticancer
agents.[4] Two ruthenium compounds have even completed
phase I clinical trials.[5,6] The biological properties of ruthe-
nium complexes have been extensively studied, with a focus
on how such compounds interact with DNA,[7] and they are
known to enter the cells through various pathways.[8,9] Con-
sequently, a cage built with cell permeate ruthenium com-
plexes could be a vehicle of choice for hydrophobic mole-
cules.
The synthesis of the metalla-cage compound [pyrene-
R1]6+ encapsulating 1-(4,6-dichloro-1,3,5-triazin-2-yl)pyr-
ene (pyrene-R) follows a two step strategy in which the di-
nuclear 2,5-dihydroxy-1,4-benzoquinonato (C6H2O4) com-
plex [Ru2(p-iPrC6H4Me)2 ACHTUNGTRENNUNG(C6H2O4)Cl2] is used as a bi-metal-
lic connector (See Scheme 1).[2] The hexacationic carceplex
system is isolated in good yield and characterised as the tri-
flate salt, [pyrene-R1]ACHTUNGTRENNUNG[CF3SO3]6. The 1H NMR spectrum
of [pyrene-R1]6+ in [D6]acetone shows broad signals for
the protons of the encapsulated pyrenyl derivative as well as
for the cage protons. The chemical shifts observed for both
pyrene-R and cage 16+ are consistent with the encapsulation
of a functionalised pyrenyl derivative.[10] The encapsulation
of pyrene-R in 16+ is further confirmed by ESI-MS in which
peaks corresponding to [pyrene-R1+ (CF3SO3)3]3+ and
[pyrene-R1+ (CF3SO3)2]4+ are observed at m/z 1081.4 and
773.8, respectively.
To determine appropriate working concentrations for sub-
sequent investigations, the cytotoxicity of the different com-
pounds, pyrene-R, [1]ACHTUNGTRENNUNG[CF3SO3]6, and [pyrene-R1]-
ACHTUNGTRENNUNG[CF3SO3]6, were determined. As shown in Table 1, pyrene-R
alone does not show any measurable IC50 value at the con-
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centrations used (up to 20 mm), whereas the cage compound
16+ showed a moderate cytotoxicity on human ovarian
A2780 cancer cells. However, [pyrene-R1]6+ shows en-
hancement of its activity as compared to the empty cage,
suggesting that the cage facilitates uptake of the poorly solu-
ble pyrene-R compound into the cells.
Based on these results, we studied the uptake of pyrene-R
and [pyrene-R1]6+ , taking advantage of the natural fluo-
rescence of pyrene-R. Interestingly, as shown in Figure 1 the
pyrene-R inside the cage does not show fluorescence at
pH 2 or pH 7, but at pH 12 it exhibits the typical fluores-
cence of pyrene-R alone. The cage compound 16+ does not
show any fluorescence when excited at 350 nm (data not
shown). This would suggest that once trapped inside the
cage the fluorescence of the pyrene-R guest molecule is
quenched and upon destruction of the cage complex at
pH 12, the fluorescence is due to free pyrene-R.
Accordingly, the free pyrene-R was tracked by fluores-
cence microscopy following incubation with A2780 cells
(Figure 2). An increase of fluorescence is observed inside
the cells following treatment with [pyrene-R1]6+ , whereas
treatment with pyrene-R at the same concentration only
shows a modest effect. It is also noteworthy that for
[pyrene-R1]6+ accumulation in cytoplasmic organelles is
observed.
Recently, Puckett et al. used flow cytometry to quantify
the uptake of a fluorescent polypyridyl ruthenium com-
pound.[8] We exploited their technique to confirm the data
obtained by microscopy and provide a more quantitative
picture. Figure 3 shows typical
histograms obtained from the
fluorescence of cells treated
with pyrene-R and [pyrene-
R1]6+ . These data confirm the
higher fluorescence of cells
treated with the encapsulated
pyrene-R in 1 and allowed the
uptake of the fluorophore to be
quantitatively assessed.
Small molecules can enter
cells in multiple ways, including
active, that is, energy-depen-
dent (endocytosis), or energy-
independent phenomena (pas-
sive diffusion or assisted diffu-
sion).[8,11, 12] To provide insights
into the uptake mechanism, the mean fluorescence, and ac-
cordingly the uptake/release of pyrene-R, as a function of
concentration and time was monitored during incubation
with [pyrene-R1]6+ and during chase (Figure 4). Figure 4
(top) shows that the uptake of the cage does not increase
linearly with incubation time. This observation implies that,
at least in part, the cellular machinery is involved, for exam-
ple, membrane transporters or receptors that limited the
rate of uptake. This inference is confirmed by the fact that
the fluorescence of the cell does not follow linearly with the
concentration of [pyrene-R1]6+ (Figure 4, middle). Never-
theless, at the concentrations tested it is not possible to de-
termine if the uptake reaches a plateau or increases linearly
at higher concentrations. Thus we cannot completely ex-
clude a passive component in the mechanism of uptake,[12]
Scheme 1. Synthesis of [pyrene-R1] ACHTUNGTRENNUNG[CF3SO3]6.
Table 1. Cytotoxicity of pyrene-R, [1]6+ and [pyrene-R1]6+ in human
ovarian A2780 cancer cells.[a]
Compound IC50 (mm)
pyrene-R >20
[1] ACHTUNGTRENNUNG[CF3SO3]6 162.3
[pyrene-R1] ACHTUNGTRENNUNG[CF3SO3]6 60.8
[a] Experiments were conducted in triplicate wells and repeated twice.
Figure 1. Fluorescence spectra of pyrene-R and [pyrene-R1]6+ at vari-
ous pH, from 2 to 12. a) Fluorescence spectrum of pyrene-R at pH 12; b)
fluorescence spectrum of [pyrene-R1]6+ at pH 12; c) fluorescence spec-
tra of [pyrene-R1]6+ at pH 2 and 7 which do not show significant fluo-
rescence.
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although an assisted diffusion pathway fits best with the ob-
tained data. It is worth noting that at 4 8C neither uptake
nor chase of pyrene-R seems to be significantly altered com-
pared to the values obtained at 37 8C. Hence endocytosis
may be disqualified as uptake does not require energy.
In conclusion, direct evidence for the efficient release of a
hydrophobic molecule from a metalla-cage following uptake
into a cell is provided. Employing a fluorescent molecule as
a cargo we have been able to increase its cytotoxicity, in-
crease its cellular uptake and to monitor its accumulation in
the cells by microscopy and flow cytometry. Furthermore,
these results suggest that the entry of the compound into
the cell is, at least in part, dependent on an assisted diffusion
pathway. This mode of uptake has been described for cispla-
tin[13] and other platinum-based drugs,[14] for which potential
transporters have been identified.[15] The existence of a fa-
cilitated mode of entry into cells implies a certain cell spe-
cificity, which offers a potential advantage for the use of
such a delivery vehicle in medicinal applications.[15]
Figure 2. Microscopy images of cells incubated with pyrene-R, [1]6+ and
[pyrene-R1]6+ , transmitted light (left) and fluorescent light (right).
Figure 3. Flow cytometry analysis of the fluorescence of the A2780 cells
treated with [pyrene-R1]6+ (a) and pyrene-R alone (b).
Figure 4. Influence of various treatments on the fluorescence of cells
treated with [pyrene-R1]6+ . The mean fluorescence of the cells was
quantified by flow cytometry. Top: Time course of release of pyrene-R in
cells treated with 2 or 4 mm of [pyrene-R1]6+ (& and ~, respectively).
Middle: Concentration dependency of the release of pyrene-R in cells
treated with [pyrene-R1]6+. Bottom: Monitoring of pyrene-R fluores-
cence during uptake at either 37 8C or 4 8C (^ and &, respectively) and
during chase after 1 hour incubation with 4 mm of [pyrene-R1]6+ at
37 8C or 4 8C (~ and  , respectively).
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Experimental Section
All organic solvents were degassed and saturated with nitrogen prior to
use. 1-(4,6-Dichloro-1,3,5-triazin-2-yl)pyrene (pyrene-R) was purchased
from Fluka. 2,4,6-Tris(pyridin-4-yl)-1,3,5-triazine (tpt)[16] and [Ru2(p-
iPrC6H4Me)2 ACHTUNGTRENNUNG(C6H2O4)Cl2]
[1] were prepared according to published meth-
ods. NMR spectra were recorded on a Bruker 400 MHz spectrometer. IR
spectra were recorded on a Perkin–Elmer 1720X FT-IR spectrometer
(4000–400 cm1). Microanalyses were performed by the Laboratory of
Pharmaceutical Chemistry, University of Geneva (Switzerland). Electro-
spray mass spectra were obtained in positive-ion mode with an LCQ Fin-
nigan mass spectrometer.
[pyrene-R1]ACHTUNGTRENNUNG[CF3SO3]6 : A mixture of [Ru2(p-iPrC6H4Me)2ACHTUNGTRENNUNG(C6H2O4)Cl2]
(50 mg, 0.075 mmol) and AgCF3SO3 (40 mg, 0.16 mmol) in MeOH
(20 mL) was stirred for 2 h, then filtered. Next, tpt (15 mg, 0.05 mmol)
and 1-(4,6-dichloro-1,3,5-triazin-2-yl)pyrene (11 mg, 0.03 mmol) were
added to the red filtrate. The mixture was stirred at RT overnight and the
solvent was removed under vacuum. The dark residue was re-dissolved in
CH2Cl2 (20 mL) and after filtration, the solution was concentrated
(5 mL), and diethyl ether was added to precipitate the red solid. Yield
59 mg, 65%; 1H NMR (400 MHz, [D6]acetone, 25 8C): d=8.54 (br, 12H;
Ha), 8.00 (br, 12H; Hb), 6.20 (d,
3J ACHTUNGTRENNUNG(H,H)=6.0 Hz, 12H; Har), 6.18 (s, 6H;
Hq), 5.98 (d,
3J ACHTUNGTRENNUNG(H,H)=6.0 Hz, 12H; Har), 2.97 (sept,
3J ACHTUNGTRENNUNG(H,H)=6.7 Hz,
6H; CH), 2.21 (s, 18H; CH3), 1.39 ppm (d,
3J ACHTUNGTRENNUNG(H,H)=6.7 Hz, 36H; CH3);
13C {1H} NMR (100 MHz, [D6]acetone, 25 8C): d=184.37, 154.07, 124.31,
104.25, 102.19, 99.34, 83.93, 82.37, 31.29, 21.69, 17.31 ppm; IR (KBr): n˜=
1523 (s), 1377 (s), 1258 (s), 1224 (w), 1159 (w), 1030 (m), 811 (w),
638 cm1 (w); ESI-MS: m/z (%): 1081.4 (100) [pyrene-R1+
(CF3SO3)3]
3+ , 773.8 (35) [pyrene-R1+ (CF3SO3)2]4+ ; elemental analysis
calcd (%) for C139H123Cl2F18N15O30Ru6S6: C 45.18, H 3.36, N 5.69; found:
C 44.83, H 3.19, N 5.93.
Cell culture and inhibition of cell growth : Human A2780 ovarian carcino-
ma cells were obtained from the European Centre of Cell Cultures
(ECACC, Salisbury, UK) and maintained in culture as described by the
provider. The cells were routinely grown in RPMI 1640 medium contain-
ing 10% foetal calf serum (FCS) and antibiotics at 37 8C and 6% CO2.
For the evaluation of growth inhibition tests, the cells were seeded in 96-
well plates and grown for 24 h in complete medium. Complexes were
added to the required concentration and added to the cell culture for
72 h incubation. Solutions of the compounds were applied by diluting a
freshly prepared stock solution of the corresponding compound in
DMSO, with the final concentration of <0.05% in the medium. The
MTT test was performed in the last 2 h without changing the culture
medium. Following drug exposure, MTT (Sigma) was added to the cells
at the final concentration of 0.2 mgmL1 and incubated for 2 h, then the
culture medium was aspirated and the violet formazan precipitate dis-
solved in DMSO. The optical density was quantified at 540 nm using a
multiwell plate reader (iEMS Reader MF, Labsystems, US), and the per-
centage of surviving cells was calculated from the ratio of the absorbance
of treated to untreated cells. The IC50 values for the inhibition of cell
growth were determined by fitting the plot of the percentage of surviving
cells against the drug concentration using a sigmoidal function (Origin
v7.5).
Microscopy experiments : Cells were grown for 24 h on chambered cover-
glass slides (Lab-Tek, NUNC) in complete medium at the density of 1.104
and then exposed to the appropriate compounds at 37 8C in the dark.
Excess complex was removed with PBS, fixed with 4% formaldehyde in
PBS for 30 min in the dark and rinsed twice with PBS before observa-
tion. Cells were mounted in PBS before being observed by fluorescence
microscopy using a Zeiss Axiovert 200m microscope equipped with a
40X air immersion objective. Filters used for excitation and detection of
DAPI were 345 nm and 448 nm, respectively. Fluorescence signal intensi-
ties were evaluated using MetaMorph software.
Flow cytometry : Cells were detached from culture with EDTA (0.48 mm
in PBS) and incubated at 1106 cellsmL1 with the compound (added
from a concentrated DMSO stock solution), under conditions described
above, and then placed on ice. The fluorescence of 20000 cells was
measured using a BD LSR II analyser, exciting with the 355 nm laser for
pyrene-R. Emission was observed at 450/40 nm. Fluorescence data were
analysed using the FlowJo 8 software. Fluorescence data are reported as
the mean.
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